Company to Present at BIO Investor Forum and Major Rheumatology Conference
Westfield, NJ / ACCESSWIRE / October 6, 2014 / Relburn-Metabolomics, Inc., an emergent life-science company focused on improving health for patients with metabolic and inflammatory diseases, will update the Company’s scientific progress and plans for clinical development at two major meetings this Fall. The initial presentation will be to the financial community in an oral presentation at the BIO Investor Forum in San Francisco on Wednesday October 8, 2014 at 11:45 AM PT, where the Company will characterize the market opportunity for its best-in-class compounds. The second presentation will be to the clinical and scientific community at the annual meeting of the American College of Rheumatology in Boston at an oral presentation on November 16, 2014 at 2:30 PM ET. Both presentations will feature Relburn’s Chief Executive Officer, Dr. Raymond P. Warrell, Jr. Separately, the Company also announced the expected filing this month of its third patent on compositions, methods, and uses of a new compound library.
Relburn’s lead program is focused on the development of disease-transforming therapy for chronic gout – a disease whose prevalence is doubling every 10 years and currently afflicts up to 16 million subjects in major markets. Gout is caused by excess uric acid (UA) in blood and connective tissues that leads to painful destructive arthritis, kidney failure, and possibly accelerated cardiovascular disease. Standard treatment seeks to reduce UA production or promote UA excretion, and benchmark drugs with these activities are allopurinol and lesinurad, respectively. Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on both production and excretion of UA. Targeting the enzymes that mediate these activities, Relburn compounds are approximately 10-fold more potent than benchmark drugs, which has yielded exceptional clinical activity.
Gout treatment is focused on reducing UA to specific target serum levels (i.e., less than 6 mg/dL). Clinical trials with the Relburn prototype drug in more than 350 patients showed that serum UA was routinely reduced to levels less than 1.0 mg/dL. With this "clinical proof-of-concept", Relburn has synthesized compound libraries that enhance clinical potency and reduce potential side-effects, which are covered by composition patent applications that are exclusively owned by the Company. Monotherapy with these drugs could potentially replace standard first-line treatments for gout and meaningfully improve clinical outcomes for patients.
Further information about Relburn-Metabolomics, Inc. can be accessed at: www.relburn.com. Information about the BIO 2014 Investor Forum is available at: http://www.bio.org/events/conferences/13th-annual-bio-investor-forum. The American College of Rheumatology (ACR) is the major clinical and scientific society of physicians specialized in metabolic and inflammatory diseases associated with joints and connective tissue. Information about the ACR is available at: http://www.rheumatology.org/.
This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets, or future developments, and are not statements of historical fact. The words "potentially", "anticipates", "expects", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.
CONTACT: Relburn Investor Relations: [email protected]
SOURCE: Relburn-Metabolomics(R) Inc.